Obstetrics & Gynecology

News and Events

Programs and providers of Obstetrics and Gynecology at Weill Cornell Medicine are often the focus of news stories and features appearing in major national media. We invite you to review some stories that typify the breakthrough accomplishments of our remarkable team and highlight the impact our care has had on patient’s lives.

Pioneering Physician-Scientist Dr. Julianne Imperato-McGinley Reflects on Her Career Successes

Dr. Imperato-McGinley

Video of Weill Cornell Medicine Honors Dr. Julianne Imperato-McGinley

A 2023 video honors Dr. Julianne Imperato-McGinley's storied career.

As a new endocrinology fellow at what is now Weill Cornell Medicine in the early 1970s, Dr. Julianne Imperato-McGinley hit a wall.

Her first assignment was to write a grant proposal, something she had never done. Over many months, she agonized over every word, tossing many revisions in the trash. Finally, Dr. Imperato-McGinley told her chief she simply couldn’t do it, that he’d picked the wrong person for the job. But he had discovered her almost-daily versions of the document in the wastebasket, fishing them out. “How about sending your version 23?” he asked with a wry smile.

Dr. Imperato-McGinley

Dr. Imperato-McGinley as an endocrinology fellow at Weill Cornell in 1972.

Mapping Human Bone Marrow Yields New Tool, Insights on Blood Cancer

cells stained blue, green and magenta

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms. The method, published June 30 in Leukemia, compares the physical locations and morphometric (size and shape) characteristics of every hematopoietic cell in the patient’s bone marrow sample with those in healthy bone marrow, to generate a score that reflects disease severity.

Myelodysplastic neoplasms (MDS) is a form of blood cancer that usually affects older adults. About one-third of patients progress to a more aggressive cancer called acute myeloid leukemia. MDS patients must undergo frequent biopsies to identify signs of remission or worsening disease. 

headshot of a man

Dr. Sanjay Patel

Tumor Organoid Tech Advances Toward a Sci-Fi Future

clumps of cells stained blue and pink

Significant advances have been made in the development of patient-derived tumor organoids for preclinical research, in two new studies led by Weill Cornell Medicine investigators. The advances represent progress in precision medicine and point to the more routine use of tumor organoids as models for evaluating and optimizing cancer treatments.

headshot of a woman

Dr. M. Laura Martin

Contact Us